Allogene hit with FDA clinical hold after a patient experiences 'abnormality' in CAR-T cells — shares hammered

John Carroll

Editor & Founder

The FDA has slapped a clinical hold on Allogene’s clinical trials after a patient in one of their early-stage studies for the off-the-shelf cell therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Allogene hit with FDA clinical hold after a patient experiences 'abnormality' in CAR-T cells — shares hammered

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Al­lo­gene hit with FDA clin­i­cal hold af­ter a pa­tient ex­pe­ri­ences 'ab­nor­mal­i­ty' in CAR-T cells — shares ham­mered

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Allogene hit with FDA clinical hold after a patient experiences 'abnormality' in CAR-T cells — shares hammered